Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?

Larry Siref, Horst Zincke

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.

Original languageEnglish
Pages (from-to)309-311
Number of pages3
JournalUrology
Volume31
Issue number4
DOIs
StatePublished - 1988

Fingerprint

Cystectomy
Adjuvant Chemotherapy
Urinary Bladder Neoplasms
Neoplasms
Vinblastine
Ploidies
Methotrexate
Doxorubicin
Cisplatin
Drug Therapy
DNA

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy? / Siref, Larry; Zincke, Horst.

In: Urology, Vol. 31, No. 4, 1988, p. 309-311.

Research output: Contribution to journalArticle

@article{396add0610a946dfb02df06b45312ed6,
title = "Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?",
abstract = "Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 {\%}) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 {\%}) had grade 3 disease or higher. Overall, in 17 (53 {\%}) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 {\%}) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.",
author = "Larry Siref and Horst Zincke",
year = "1988",
doi = "10.1016/0090-4295(88)90087-8",
language = "English",
volume = "31",
pages = "309--311",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?

AU - Siref, Larry

AU - Zincke, Horst

PY - 1988

Y1 - 1988

N2 - Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.

AB - Of 695 patients who, in a five-year period, underwent cystectomy for bladder cancer, 32 (4.6 %) proved to have historical and pathologic Stage T1 (Stage A) transitional cell cancer. Of these, 23 (72 %) had grade 3 disease or higher. Overall, in 17 (53 %) progression developed after follow-up of ≥ 5 years. Moreover, in 10 (31 %) of the patients systemic progression developed during ten years. DNA ploidy pattern analysis did not prove helpful in predicting disease outcome. Because effective systemic chemotherapy has become available in the form of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), it seems justifiable that patients who are considered to be candidates for cysteetomy because of high-grade, multifocal TI transitional cell cancer of the bladder also could be candidates for effective neo-adjuvant chemotherapy, in addition to those who usually are part of these protocols-namely, those with ≥ T2 disease.

UR - http://www.scopus.com/inward/record.url?scp=0023939766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023939766&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(88)90087-8

DO - 10.1016/0090-4295(88)90087-8

M3 - Article

VL - 31

SP - 309

EP - 311

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -